Design of plasmid DNA as non-viral gene therapeutics - Inospin | Inospin
Logo Inospin

Inospin : THE #1 ACADEMIA-INDUSTRY PARTNERING NETWORK FOR SCIENTIFIC INNOVATIONS

The worldwide platform to find industrial partners and funding

External open innovation partner programDesign of plasmid DNA as non-viral gene therapeutics
Do you have plasmid deign knowledge/experience that can contributes to explore multiple transgene expression in both non-dividing and dividing cells with high efficiency in a controlled manner? Are you interested in partnering with a pharma to transform your proprietary science into a novel therapeutics?
What we are looking for

We are looking for a novel plasmid DNA technology to explore non-viral gene therapeutics.

We are specifically interested in the following plasmid design technologies:
- Non-viral gene platform (improved plasmid) except minicircle, mini-intronic plasmid, ministring, MIDGE, cDNA;
- Episomal vector for sustained transgene expression at least during a month in dividing cells without integration to host genome;
- Biodegradable plasmid that can be eliminated after certain period of time;
- Multigene plasmid (more than 3 transgenes) of which antibiotic marker can be eliminated;
- Plasmid with efficient nuclear translocation with high transfection efficiency in non-dividing cells;
- On/off switch for transgene expression without using non-mammalian system.

What we offer and how does it work

All proposals will be assessed by our Research & Development team. Based on the level of interest within the Company research portfolio and strategic fit, we will enter into discussion with selected candidate(s), potentially leading to partnership agreements or collaborations.

Proponents that submit proposals of interest will be contacted within 8 weeks of submission to clarify additional details.

What to submit

Submit a proposal in a form which is available online (it takes about 15 minutes). The proposal should be brief, sufficient to provide the main body of the proposal and its innovativeness. The applicant should also provide information about his or her critical knowledge that is applicable for the project, and how the knowledge could be supplemented (i.e., what is additionally required to complete the project). The applicants are strongly encouraged to give us additional information including references or other materials to facilitate the evaluation process.

Privacy, confidentiality & FAQ

The Company will not share the information beyond its own dedicated evaluation team; your initial proposal should contain only non-confidential information.
If your proposal is selected, the Company considers to execute a Confidentiality Disclosure Agreement (CDA).

Inospin

Biowebspin pays a lot of attention to the privacy, intellectual property, confidentiality and security of its member data. Biowebspin is a matchmaking platform between academia & industry. Biowebspin is not involved in the IP discussion and is not charging any success or license fees. Your «Open Innovation» opportunities on Biowebspin are only visible by industrials and the Biowebspin team. You can remove your data at any time. Biowebspin strongly recommends that you do not enter any confidential data or if you do so, that your technology transfer office agrees the submission of your pre-proposal on Biowebspin. If you directly submit your pre-proposal on an industrial partner website, you will agree their terms, conditions and privacy policy of our industrial partner website. Biowebspin is not responsible for the content, accuracy, or opinion of its industrial partner website. As a Swiss International company, Biowebspin has high standard security and privacy system. Biowebspin is in accordance with the Federal Data Protection and Information Commissioner. Contact us for more information about the terms and conditions of the matchmaking service of Biowebspin.